July 29, 2026— Kellogg Hansen associate Jimmy A. Ruck served as a panelist on BARBRI’s continuing legal education program, “Personal Injury From Failure to Warn: Drug Label Litigation Under State Law and Impossibility Preemption.” Alongside partners from firms around the country, Jimmy discussed how courts address the drug manufacturer’s impossibility preemption defense in personal injury lawsuits in the wake of recent decisions. Drawing on his experience successfully litigating preemption cases, Jimmy advised plaintiffs on developing fact and discovery strategies to survive summary judgment and how to navigate complex legal issues at the intersection of administrative law and science.

The CLE focused on ongoing challenges in litigating state‑law failure‑to‑warn claims when drug manufacturers argue that FDA action makes compliance with state law labeling duties impossible. In particular, the panel discussed the impact of the Third Circuit’s decision in In re Fosamax (Alendronate Sodium) Products Liability Litigation, an appeal Kellogg Hansen won.

Jimmy represents both plaintiffs and defendants in trial and appellate courts.  At the trial level, he handles every phase of litigation, from the complaint stage to examining witnesses at trial.  At the appellate level, he has briefed in multiple courts of appeals and in the United States Supreme Court, and successfully argued a precedent-setting victory in a federal court of appeals.  Jimmy has particular experience with complex commercial disputes, securities, and antitrust litigation, representing clients in the financial, telecommunications, and technology industries.

The full CLE program is available here: Personal Injury From Failure to Warn: Drug Label Litigation Under State Law and Impossibility Preemption – Product Info – Barbri – Barbri Portal